Abstract
Despite the concerted efforts of modern medicine, infections due to gram-positive bacteria, such as skin and soft tissue infections, pneumonia, bacteremia, and endocarditis, continue to pose many challenges to achieving successful treatment outcomes. A good case in point is found in the emergence and spread of methicillin resistance in Staphylococcus aureus. The first strains of methicillin-resistant S. aureus (MRSA) were discovered a half-century ago in a hospital in London, just 2 years after the first clinical use of methicillin [1]. During the ensuing 50 years, these organisms have spread worldwide despite extensive attempts to control them. In some of the Scandinavian countries and the Netherlands, “search and destroy” efforts in hospitals have been successful in controlling infections caused by MRSA. This was aided by the fact that most MRSA infections were hospital acquired. That situation, however, began to change in the early 1990s, when infections due to MRSA were noted in patients without previous inpatient healthcare exposure across 6 different continents, including Australia, where several outbreaks were detected in Western Australia and the Northern Territory [2, 3]. Community-acquired (or community-associated) MRSA (CA-MRSA) subsequently spread throughout North America, where one particular clone (USA-300) quickly established dominance. Not surprisingly, these strains have also spread to Europe, where they have caused significant problems due to the fact that European guidelines for infection control have been geared to inpatient rather than outpatient acquisition of methicillin-resistant strains [4].

This publication has 15 references indexed in Scilit: